Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer - guidance (TA621)

Source:
National Institute for Health and Care Excellence - NICE
Publication date:
22 January 2020

Abstract

Evidence-based recommendations on osimertinib (Tagrisso) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults.

Is this guidance up to date?

Next review: 2023

Guidance development process

How we develop NICE technology appraisal guidance